Amicus Therapeutics, Inc. $FOLD Shares Bought by Wrapmanager Inc.

Wrapmanager Inc. raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 41.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,165 shares of the biopharmaceutical company’s stock after purchasing an additional 6,475 shares during the period. Wrapmanager Inc.’s holdings in Amicus Therapeutics were worth $127,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of FOLD. Wellington Management Group LLP increased its holdings in Amicus Therapeutics by 2.6% in the first quarter. Wellington Management Group LLP now owns 29,200,617 shares of the biopharmaceutical company’s stock valued at $238,277,000 after buying an additional 738,623 shares during the last quarter. Redmile Group LLC increased its holdings in shares of Amicus Therapeutics by 35.1% in the 1st quarter. Redmile Group LLC now owns 9,533,669 shares of the biopharmaceutical company’s stock valued at $77,795,000 after acquiring an additional 2,478,779 shares during the last quarter. Vestal Point Capital LP raised its position in shares of Amicus Therapeutics by 27.6% during the 1st quarter. Vestal Point Capital LP now owns 4,275,000 shares of the biopharmaceutical company’s stock worth $34,884,000 after acquiring an additional 925,000 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Amicus Therapeutics by 641.2% during the second quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company’s stock worth $20,249,000 after purchasing an additional 3,057,072 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Amicus Therapeutics in the 1st quarter valued at about $28,741,000.

Amicus Therapeutics Stock Up 1.1%

Shares of NASDAQ:FOLD opened at $9.48 on Friday. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $10.35. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. The firm’s 50-day simple moving average is $8.45 and its 200-day simple moving average is $7.16. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -78.99 and a beta of 0.66.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.The company had revenue of $169.06 million for the quarter, compared to analysts’ expectations of $165.24 million. During the same quarter in the previous year, the firm posted $0.10 EPS. The firm’s quarterly revenue was up 19.5% on a year-over-year basis. Amicus Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on FOLD shares. Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amicus Therapeutics in a report on Thursday. Wall Street Zen upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Needham & Company LLC upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Thursday, September 18th. Finally, JPMorgan Chase & Co. increased their target price on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Insider Activity

In related news, insider David Michael Clark sold 25,643 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $9.51, for a total value of $243,864.93. Following the sale, the insider owned 322,618 shares of the company’s stock, valued at approximately $3,068,097.18. This represents a 7.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.20% of the stock is owned by corporate insiders.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.